A review of clinical characteristics and genetic backgrounds in Alport syndrome by 長田 道夫 et al.
A review of clinical characteristics and
genetic backgrounds in Alport syndrome
著者（英） Kandai Nozu, Koichi Nakanishi, Yoshifusa Abe,
Tomohiro Udagawa, Shinichi Okada, Takayuki
Okamoto, Hiroshi Kaito, Katsuyoshi Kanemoto,
Anna Kobayashi, Eriko Tanaka, Kazuki Tanaka,
Taketsugu Hama, Rika Fujimaru, Saori Miwa,
Tomohiko Yamamura, Natsusmi Yamamura, Tomoko
Horinouchi, Shogo Minamikawa, Michio NAGATA,
Kazumoto Iijima
journal or
publication title
Clinical and experimental nephrology
volume 23
number 2
page range 158-168
year 2018-02
権利 (C) The Author(s) 2018
This article is distributed under the terms of
the Creative Commons Attribution 4.0
International License (http://creat iveco
mmons .org/licen ses/by/4.0/), which permits
unrestricted use, distribution, and
reproduction in any medium, provided you give
appropriate credit to the original author(s)
and the source, provide a link to the Creative
Commons license, and indicate if changes were
made.
URL http://hdl.handle.net/2241/00154947
doi: 10.1007/s10157-018-1629-4
Creative Commons : 表示
http://creativecommons.org/licenses/by/3.0/deed.ja
Vol:.(1234567890)
Clinical and Experimental Nephrology (2019) 23:158–168
https://doi.org/10.1007/s10157-018-1629-4
1 3
INVITED REVIEW ARTICLE
A review of clinical characteristics and genetic backgrounds in Alport 
syndrome
Kandai Nozu1  · Koichi Nakanishi2 · Yoshifusa Abe3 · Tomohiro Udagawa4 · Shinichi Okada5 · Takayuki Okamoto6 · 
Hiroshi Kaito1 · Katsuyoshi Kanemoto7 · Anna Kobayashi8 · Eriko Tanaka4 · Kazuki Tanaka9 · Taketsugu Hama10 · 
Rika Fujimaru11 · Saori Miwa12 · Tomohiko Yamamura1 · Natsusmi Yamamura13 · Tomoko Horinouchi1 · 
Shogo Minamikawa1 · Michio Nagata14 · Kazumoto Iijima1
Received: 12 April 2018 / Accepted: 6 August 2018 / Published online: 20 August 2018 
© The Author(s) 2018
Abstract
Alport syndrome (AS) is a progressive hereditary renal disease that is characterized by sensorineural hearing loss and ocular 
abnormalities. It is divided into three modes of inheritance, namely, X-linked Alport syndrome (XLAS), autosomal recessive 
AS (ARAS), and autosomal dominant AS (ADAS). XLAS is caused by pathogenic variants in COL4A5, while ADAS and 
ARAS are caused by those in COL4A3/COL4A4. Diagnosis is conventionally made pathologically, but recent advances in 
comprehensive genetic analysis have enabled genetic testing to be performed for the diagnosis of AS as first-line diagnosis. 
Because of these advances, substantial information about the genetics of AS has been obtained and the genetic background 
of this disease has been revealed, including genotype–phenotype correlations and mechanisms of onset in some male XLAS 
cases that lead to milder phenotypes of late-onset end-stage renal disease (ESRD). There is currently no radical therapy for 
AS and treatment is only performed to delay progression to ESRD using nephron-protective drugs. Angiotensin-converting 
enzyme inhibitors can remarkably delay the development of ESRD. Recently, some new drugs for this disease have entered 
clinical trials or been developed in laboratories. In this article, we review the diagnostic strategy, genotype–phenotype cor-
relation, mechanisms of onset of milder phenotypes, and treatment of AS, among others.
Keywords Genotype–phenotype correlation · Thin basement membrane · ACE inhibitor · Bardoxolone
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Introduction
Alport syndrome (AS) is a progressive hereditary renal 
disease accompanied by sensorineural hearing loss and 
ocular abnormalities. AS develops because of patho-
genic variants in the COL4A3, COL4A4, and COL4A5 
genes encoding type IV collagen α3, α4, and α5 chains, 
respectively [1–3]. These type IV collagens constitute the 
glomerular basement membrane (GBM). AS has been 
reported to develop in approximately one in 5000 peo-
ple; it comprises 0.5% of newly developed end-stage renal 
disease (ESRD) cases in adults [4] and 12.9% in children 
[5]. Type IV collagen has six different α chains, α1 to α6, 
which construct triple helix structures in which the three 
chains are combined. The combination of three α-chains is 
organ-specific: in the GBM, cochlea basement membrane, 
and base of the ocular lens, the triplet α3–α4–α5 is pre-
sent, while in Bowman’s capsule and skin basement mem-
brane, it is α5–α5–α6. When an abnormality occurs in the 
α-chain, these triple helix structures are broken, causing 
nephropathy, sensorineural hearing loss, and eye lesions. 
AS is divided into X-linked Alport syndrome (XLAS), 
autosomal recessive AS (ARAS), and autosomal dominant 
AS (ADAS), according to its mode of inheritance. The 
distribution of these cases is reported to be as follows: 
80% XLAS, 15% ARAS, and 5% ADAS. XLAS is caused 
by abnormality of COL4A5, while ADAS and ARAS are 
caused by abnormality in COL4A3 or COL4A4 [3].
Clinical characteristics and diagnostic 
features
Table 1 shows the diagnostic features established by the 
members of the Working Group for Alport Syndrome in 
the Japanese Society of Pediatric Nephrology (JSPN) 
in 2015 [6]. The main criterion is persistent hematuria. 
When patients fulfill one or more secondary features, or 
two or more accessory features, in addition to the primary 
feature, they can be diagnosed with AS. Symptoms differ 
depending on the mode of inheritance, with their features 
described below.
1) XLAS
In XLAS, there is often a family history of hematu-
ria (with or without proteinuria) or renal failure. How-
ever, in approximately 15% of cases, there are de novo 
variants without a family history [3]. Microscopic hema-
turia is observed in all male cases. In female patients, it 
is observed in approximately 98% with hematuria and 
Table 1  Diagnostic features of Alport syndrome (revised in Febru-
ary 2015) prepared by the Working Group on Alport Syndrome of the 
Japanese Society of Pediatric Nephrology
In addition to the primary feature, patients satisfy one or more sec-
ondary features
If there is no corresponding item in secondary features, patients 
should satisfy two or more of the accessory features
If patients have only the primary feature and have a family member 
diagnosed with Alport syndrome, the case is set as a “suspected case”
Asymptomatic carriers can be diagnosed with any one feature of type 
IV collagen (II-1 or II-2) among the secondary features
For all features, those caused by other diseases should be excluded, 
for example, a family history of kidney failure due to diabetes or 
senile deafness
*1 Persisted for more than 3 months, which was confirmed by uri-
nalysis on at least two occasions. As a rare situation, there is a pos-
sibility that hematuria may disappear at the time when renal failure 
progresses to the end stage, in which case appropriate examination 
such as of kidney dysfunction should be performed
*2 This refers to a homozygous or heterozygous mutation of COL4A3 
or COL4A4, or a hemizygous (male) or heterozygous (female) muta-
tion of the COL4A5 gene
*3 Type IV collagen α5 chain exists not only in the glomerular base-
ment membrane and Bowman’s capsule, but also in the skin basement 
membrane. Upon immunostaining using anti-α5-chain antibody, normal 
glomeruli and skin basement membrane are stained linearly and continu-
ously. However, glomeruli, Bowman’s capsule, and the skin basement 
membrane of male patients with X-linked Alport syndrome are com-
pletely negative. In glomeruli, Bowman’s capsule and skin basement 
membrane of female patients are partially stained. In autosomal recessive 
Alport syndrome, the α3-, α4-, and α5 chains are not stained in glomeru-
lar basement membranes, whereas in Bowman’s capsule and skin, nor-
mal α5-chain staining is shown. Note that the above is a typical pattern, 
but an atypical pattern also exists. Moreover, Alport syndrome cannot be 
ruled out even if α5 chain expression shows completely normal pattern
*4 Glomerular basement membrane-specific abnormalities include 
broad irregular thickening of the glomerular basement membrane and 
reticulation of the lamina densa. Extensive thinning of the glomerular 
basement membrane frequently seen in benign familial hematuria is 
also seen in Alport syndrome, which can be the only finding of the 
glomerular basement membrane. In these cases, there is a high pos-
sibility of Alport syndrome if the cases show hearing loss, ocular 
abnormalities, or a family history of renal failure
*5 Specific ocular abnormalities include anterior lenticonus, posterior 
subcapsular cataract, posterior polymorphous dystrophy, and retinal 
flecks
I. Primary feature:
 I-1. Persistent hematuria *1
II. Secondary features:
 II-1. Mutations in type IV collagen genes *2
 II-2. Type IV collagen abnormal expression *3
 II-3. Glomerular basement membrane (GBM) -specific abnormalities *4
III. Accessory features
 III-1. Family history of kidney diseases
 III-2. Bilateral sensorineural deafness
 III-3. Ocular abnormalities *5
 III-4. Diffuse leiomyomatosis
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73% with both hematuria and proteinuria [7]. In male 
patients, proteinuria is recognized at an early stage of 
childhood, sometimes exhibiting a nephrotic status; it 
is also reported that 90% of patients develop ESRD by 
the age of 40 years, with the median age of development 
of ESRD being 25 years [8]. In females, 12% of cases 
have developed ESRD by the age of 40 [9]. We recently 
reported that patients exhibited proteinuria at a median 
age of 7 years, and that ESRD development occurred at a 
median of 65 years in female XLAS [7].
Sensorineural hearing loss often occurs from the latter 
stage of childhood; 90% of male patients and approximately 
12% of female patients present with hearing loss by the age 
of 40 years [8, 9]. Jais et al. reported that, in females, the 
presence of hearing loss predicts the development of ESRD; 
however, our recent study showed no significant difference 
in kidney severity between patients with and without hear-
ing loss [7, 9]. Specific ocular abnormalities, including 
anterior lenticonus, posterior subcapsular cataract, poste-
rior polymorphous dystrophy, and retinal flecks, are known 
as ophthalmologic complications; clinical symptoms, such 
as obvious visual impairment, rarely appear [10]. Other 
complications include leiomyoma due to contiguous gene 
deletion encompassing the 5′ end of COL4A5 and COL4A6 
intron 2. In this phenotype, leiomyoma is observed with full 
penetration, for which no gender difference is observed [11].
2) ARAS
Clinically, ARAS shows symptoms similar to those in 
male XLAS patients. There are no gender differences in clin-
ical symptoms and incidence, and this condition sporadically 
occurs in one generation. Families with monoallelic variant 
carriers are often asymptomatic or show only microscopic 
hematuria (and mild proteinuria) [12, 13]. For the genetic 
diagnosis of ARAS, analysis of at least one familial mem-
ber (ideally, both parents) is necessary to prove that two 
heterozygous variants are located in trans positions on two 
different alleles (either COL4A3 or COL4A4). In terms of 
the clinical findings that we previously reported, the median 
age of ESRD development is 21 years. Sensorineural deaf-
ness was observed at a median age of onset of 20 years [12].
3) ADAS
Recently, we published an article regarding the clinical 
picture, pathology, and genetic background of ADAS [14]. 
The median age for detecting proteinuria was 17.0 years, 
and that for developing renal insufficiency was 70 years. 
In addition, both hearing loss and eye lesion were reported 
to occur quite rarely. Moreover, three of 16 patients with 
pathological findings showed focal segmental glomerular 
sclerosis (FSGS), as revealed by light microscopy. It has 
also been reported that, in approximately 10% of patients 
with familial focal segmental glomerulosclerosis, COL4A3 
or COL4A4 mutations are identified, suggesting that there 
are many undiagnosed ADAS patients [15].
Pathological findings
There are no specific light microscopic findings in AS; 
nonspecific findings are observed, such as mesangial prolif-
eration, FSGS, renal tubular atrophy, foam cell formation, 
or interstitial fibrosis. Electron microscopic (EM) findings 
show irregular thickening and thinning of the GBM, and 
lamellation and splitting in lamina densa can be observed 
(Fig. 1). These findings are specific to AS and electron 
microscopic findings are indispensable for the pathological 
diagnosis of this condition. However, pathological findings 
become apparent in the form of nephritis progression, even 
in male XLAS cases or ARAS cases; for female XLAS and 
ADAS cases, typical findings of EM can be observed gener-
ally at later stages and often show only thinning of GBM. 
Therefore, careful observation is necessary, because there 
are cases with no obvious changes except for thin basement 
membrane (TBM) at the early stages of AS. Immunohisto-
logically, specific findings can be identified with α5 staining. 
Approximately 80% of XLAS male patients are completely 
negative for α5 staining, while XLAS female patients exhibit 
a mosaic pattern due to the mechanisms of X-chromosome 
inactivation that occur in female cells (Fig. 2) [2, 16]. In 
ARAS patients, the GBM is negative for α3, α4, and α5 
staining, while Bowman’s capsule is α5 positive; this is 
because the GBM consists of α3–α4–α5, but Bowman’s 
capsule consists of α5–α5–α6 and COL4A3/COL4A4 muta-
tions do not influence α5 expression in Bowman’s capsule. 
In ADAS patients, both the GBM and Bowman’s capsule 
exhibit a normal pattern of α5 expression. α5 staining is 
a useful diagnostic method, because it remains unchanged 
regardless of age; however, it should solely be used as a 
method of auxiliary diagnosis, because it can show nonspe-
cific findings, such as a normal expression pattern in more 
than 20% of XLAS males [1]. We have reported that 29% 
of male XLAS and 20% of ARAS cases showed atypical 
positive expression of α5 in GBM [12, 17]. All male XLAS 
cases with α5 positivity possessed non-truncating variants 
or somatic mosaic variants in COL4A5 and showed signifi-
cantly milder phenotypes of later-onset ESRD [17]. ARAS 
cases with α5 positivity possessed a missense variant in at 
least one allele in the COL4A3 or COL4A4 gene and again 
showed a milder phenotype that involved later development 
of ESRD [12].
Skin basement membrane consists of type IV collagen 
α5–α5–α6 triple helix. Therefore, α5 staining is a useful 
auxiliary diagnostic method only for XLAS cases: male 
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Fig. 1  Glomerular basement membrane (GBM) change in Alport 
syndrome (AS) observed by electron microscopy. A Thin basement 
membrane, which is typically observed in milder cases, including 
female X-linked AS and autosomal dominant AS. B Diffuse thicken-
ing and lamellation, which are specific findings of AS
Fig. 2  Immunohistochemical 
analysis of type IV collagen α5 
chain in glomerulus. A Normal 
control shows full expression 
in both glomerular basement 
membrane (GBM) and Bow-
man’s capsule (BC). B Male 
X-linked Alport syndrome 
(XLAS) case shows completely 
negative expression in both 
GBM and BC. C Female XLAS 
case shows a mosaic pattern of 
expression in both GBM and 
BC due to the mechanisms of 
X-chromosome inactivation 
that occur in female cells. D 
Autosomal recessive Alport 
syndrome case shows negative 
expression only on GBM and 
positivity on BC, because BC 
consists of the α5–α5–α6 triple 
helix. E Schema for X-chromo-
some inactivation (XCI). In all 
female cells, either of the two 
X chromosomes is randomly 
inactivated. When the wild-type 
chromosome has been inacti-
vated, the cell will not produce 
α5. Then, GBM and BC will be 
stained with a mosaic pattern
A B 
C D 
mutant WT mutant mutant WT WT 
WT 
mutant
WT 
mutant
E 
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XLAS cases show negativity for α5 expression, while female 
XLAS cases show a mosaic expression pattern, as observed 
in GBM (Fig. 3A, B) [2]. It should be noted that decreased 
α5 expression can be observed at the bottom of the papillary 
epidermal basement membrane in normal skin (Fig. 3C, D) 
[18].
Gene tests
Along with the progression of gene analysis technology 
in recent years, there has been remarkable development 
of the genetic diagnosis system for AS. Because all three 
of the COL4A3, COL4A4, and COL4A5 genes consist of 
approximately 50 exons, conventional Sanger sequencing 
is too laborious and time-consuming for genetic screening. 
Therefore, the main strategy for gene screening in AS has 
become targeted sequencing, which captures all exons and 
exon–intron boundaries of all three genes, along with com-
prehensive sequencing analysis by NGS. Genes responsible 
for kidney diseases that clinically or pathologically resem-
ble AS should be included in the targeted screening panel. 
For example, BOR syndrome shows nephritis and deafness; 
patients with these symptoms are sometimes suspected of 
having AS. Moreover, the pathological findings of Pierson 
syndrome frequently include lamellation of the GBM, as 
revealed by EM. Moreover, some cases of Pierson syndrome 
with missense variants in the LAMB2 gene tend to show 
milder phenotypes involving later onset of ESRD [19]. 
These clinical features resemble those of AS. Cases with 
gene variants in LMX1B (nail–patella syndrome), PAX2 
(renal coloboma syndrome), or MYH9 (MYH9 nephropa-
thy) also show lamellation of the GBM, so they should be 
included in the gene list. Most mutations detected in AS 
are novel variants, because there are no mutational hotspots 
among the three genes. When we fail to detect pathogenic 
variants by means of targeted sequencing, we must proceed 
to the next step of detecting copy number variations (CNVs) 
and deep intronic pathogenic variants. Our gene screening 
strategy for AS is as follows: Step 1: targeted next-generation 
Fig. 3  Immunohistochemical analysis of type IV collagen α5 chain 
on epidermal basement membrane (EBM). A Male X-linked Alport 
syndrome (XLAS) case shows completely negative expression on 
EBM. B Female XLAS case shows a mosaic pattern of expression 
on EBM due to the mechanisms of X-chromosome inactivation that 
occur in female cells. C Normal control shows full α5 expression on 
EBM; however, decreased α5 expression can be observed in the bot-
tom of papillary EBM in the normal skin. D Normal control shows 
full α2 expression on EBM, even at the bottom of papillary EBM
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sequencing with a custom disease panel; when pathogenic 
variants are detected, they are confirmed by Sanger sequenc-
ing. When we fail to detect mutations by Step 1, we proceed 
to Step 2, which involves conducting pair analysis compar-
ing NGS data from patients and normal controls, to screen 
for CNVs. When pair analysis shows the possibility of CNVs 
in any of the three genes, we proceed to detecting CNVs by 
multiplex ligation-dependent probe amplification (MLPA). 
When we fail to detect pathogenic variants with Steps 1 and 
2, we proceed to Step 3: reverse transcription–polymerase 
chain reaction (RT-PCR) of mRNA and direct sequencing 
to detect aberrant splicing due to intronic or exonic variants. 
With these three steps, we can detect pathogenic variants 
in any one gene for more than 90% of cases clinically sus-
pected of being AS [7, 12, 14, 20]. With Step 2, we recently 
detected CNVs in COL4A5 in AS cases [21]. Pair analysis 
also revealed a case with clinically suspected AS because of 
ESRD and hearing loss, which had CNVs in the EYA1 gene, 
and diagnosed this as BOR syndrome [21]. With Step 3, we 
have identified deep intronic variants that lead to cryptic 
exon insertion by creating novel splicing sites [12, 20]. We 
have also identified aberrant splicing caused by a so-called 
“silent variant,” an exonic single-nucleotide substitution that 
does not change the coding amino acid [22].
Genotype–phenotype correlation
Three reports have been published analyzing the correlation 
between genotype and clinical picture based on large-scale 
data in male XLAS patients; we briefly summarize them 
here.
1. In 2000, Jais et al. analyzed 401 male XLAS patients 
from 195 families. The results showed that the median 
age at developing ESRD overall was 25 years; 90% of 
patients had developed ESRD by the age of 40. Geneti-
cally, the frequencies of progression to ESRD by the 
age of 30 were (1) 90% in cases with wide deletions, 
nonsense mutations, or frameshift mutations; (2) 70% 
in cases with splice site mutations; and (3) 50% in cases 
with missense mutations. This report showed for the 
first time that the kidney prognosis differed significantly 
depending on mutation type [8].
2. In 2002, Gross et al. conducted a meta-analysis of 267 
men with XLAS, including cases that had been previ-
ously reported. They classified genetic mutations into 
the following three groups and evaluated their renal 
prognosis: (1) large rearrangements, premature stops, 
frameshift mutations, mutations of splice donor sites, or 
mutations in the NC domain (truncated protein group) 
were associated with the development of ESRD at the 
median age of 19.8 years; (2) missense mutations of 
glycine in exons 21–47, in-frame mutations, and muta-
tions involving the splicing acceptor site (altered protein 
structure group) were associated with the development 
of ESRD at the median age of 25.7 years; and (3) mis-
sense mutations of glycine of exons 1–20 were associ-
ated with the development of ESRD at the median age 
of 30.1 years [23].
3. In 2010, Bekheirnia et al. analyzed 681 male patients 
with XLAS from 175 families. The results were as fol-
lows: The median age of developing ESRD was (1) 
37 years with missense mutations, (2) 28 years with 
splice site mutations, (3) 25 years with truncating muta-
tions, and (4) 22 years with both large- and small-dele-
tion mutations. Furthermore, the position of mutations 
closer to the 5′ end tended to show earlier progression 
of ESRD; in the same analysis, limited to only missense 
mutations in glycine, there was no correlation between 
location and severity. In these respects, the results dif-
fered from those in the report by Gross et al. [24].
Regarding female XLAS cases, two previous reports 
showed no genotype–phenotype correlations [7, 9]. It has 
long been suspected that an uneven pattern of X-chromo-
some inactivation (i.e., skewed X chromosome inactiva-
tion) would influence the severity of XLAS in females 
[25]; however, no study has systematically proven the cor-
relation between a skewed X pattern and clinical severity 
in female XLAS. In our experience, X-chromosome inac-
tivation pattern analysis cannot predict kidney prognosis 
in female XLAS cases (manuscript in preparation).
For ARAS, two previous reports discussed the geno-
type–phenotype correlation in this condition.
1. In 2013, Storey et al. reported that patients with truncat-
ing mutations in at least one allele tended to show early 
onset of renal failure, compared with patients without 
truncating mutations [13].
2. In 2014, Oka et al. (our group) reported that no geno-
type–phenotype correlation was observed in ARAS 
cases, even when the patients were divided into two 
groups, similar to those of Storey et al. However, some 
cases that exhibited missense mutations in at least one 
allele showed milder phenotypes, with full expression 
of α5 on GBM [12].
In ADAS, no genotype–phenotype correlations have 
been observed thus far. Even within one family, clinical 
severity differed significantly and some individuals devel-
oped ESRD, whereas others possessing the same mutation 
showed no urinary abnormality [14].
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Mechanisms of onset of atypical mild phenotypes 
in male XLAS
It has been reported that some male XLAS cases show 
atypical mild phenotypes of late-onset ESRD. Based on 
previously reported results, it has been clarified that, for 
the following reasons, XLAS male patients may exhibit a 
mild clinical picture.
1. Cases with missense mutations
In all large-scale studies that analyzed genotype–phe-
notype correlations, it was reported that the age at which 
ESRD developed was significantly delayed in cases pos-
sessing missense mutations, as described above [8, 23, 
24]. We have reported a male patient with very mild 
XLAS who had a missense mutation (p.Gly1000Val) in 
the COL4A5 gene and only showed hematuria at the age 
of 38 years [26]. We have also encountered a 40-year-old 
male with the same mutation who only showed hematuria 
(unpublished data). Thus, some missense mutations can 
lead to extremely mild phenotypes.
2. Cases with in-frame deletion mutations
For mutations involving deletion of a multiple of three 
nucleotides, the fact that three bases code one amino acid 
means that this mutation does not significantly influence the 
subsequent amino acid sequence (i.e., no frameshift occurs). 
Such mutations are called in-frame deletion mutations. 
Gross et al. reported that, when an in-frame mutation occurs, 
the age at which ESRD develops is significantly later than in 
cases with frameshift mutations [23]. In addition, Jais et al. 
classified in-frame deletions with deleted nucleotides num-
bering from 3 to 18 bases into a missense mutation group 
and analyzed them, because they showed mild phenotypes 
[8]. We also have reported two families with mild disease 
phenotypes, the members of which progressed to end-stage 
renal failure in their 60 s and 40 s due to deletions of 9 and 
36 bases, respectively [17].
3. Cases with splice site mutations result in in-frame dele-
tion at the transcript level
Furthermore, we recently reported a male with a deletion 
of 105 bases at the mRNA level due to a splice site mutation, 
in whom ESRD had not developed at the age of 47 [20]. This 
case showed an in-frame mutation at the mRNA level, indi-
cating that mutation at a splice site may be associated with 
a mild clinical picture. Recently, we published the results 
of a large data analysis comparing splice site mutations, 
with or without in-frame deletion, at the transcript levels; 
we revealed that renal prognosis differs significantly, and 
that ESRD developed 9 years later in the in-frame deletion 
group [27].
4. Somatic cell mosaicism in proband cases
Mosaic mutations involve the presence of two cell popula-
tions with different genotypes in one individual, which have 
developed from a single fertilized egg (Fig. 4). Probands 
in cases of hereditary diseases can sometimes develop to 
retain mutants at somatic cell division failure. When this 
gene mutation is inserted after repeated cell division in 
fertilized eggs, cells with a normal gene and cells with an 
abnormal gene coexist; this is known as mosaicism. When 
this status is observed among somatic cells, it is recog-
nized as somatic mosaicism. We previously reported a male 
patient with mild XLAS who had a mutation with somatic 
mosaicism [28]. Recently, we reported a tendency for an 
association between variant allele frequency and severity 
of renal symptoms in four men with XLAS with somatic 
mosaic variants [29]. Variant allele frequency was analyzed 
by ultra-deep sequencing with NGS. One of the cases, whose 
two daughters exhibited typical findings of female XLAS, 
was completely asymptomatic.
5. A case with splice site mutation, in which both normal 
mRNA and aberrantly spliced mRNA are produced in 
renal tissue during transcription
With splice site mutations, exon skipping is usually 
observed. However, incomplete mutation of the splice site 
may produce both normal and abnormal kidney mRNA, 
leading to milder phenotypes. This mechanism has been 
reported in another inherited disease, galactosialidosis [30]. 
In this disease, the IVS8 + 9C > G variant in the CTSA gene 
produces abnormally spliced mRNA with a low level of 
mutaon
somac mosaicism
germline mosaicism
somac/germline mosaicism
somac cells germ cells
Fig. 4  Schema of genetic mosaicism. When gene mutation occurs 
after repeated cycles of cell division in fertilized eggs, cells with a 
normal gene and cells with an abnormal gene coexist; this is known 
as mosaicism. When this status occurs in somatic cells, it is recog-
nized as somatic mosaicism; in gonadal cells, it is known as germline 
mosaicism
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normal mRNA, which leads to a milder phenotype in the 
patient. A similar mechanism was also observed in a male 
XLAS case with a mild phenotype. We recently reported 
a mild XLAS case that exhibited only hematuria and very 
mild proteinuria despite being 22 years; the patient pos-
sessed a deep intronic mutation that produced both normal 
and abnormal mRNA in the kidney [20].
6. Cases with α5 expression in GBM
In a typical XLAS male patient, because of abnormality 
of the COL4A5 gene, expression of α5 is not recognized at 
all in GBM. However, the expression of α5 was confirmed 
in 29% of male XLAS patients; in those α5-positive cases, 
it was found that the age at which urinary protein was exhib-
ited was significantly older, the amount of urine protein was 
significantly lower, the age of end-stage renal failure was 
also significantly older (37 years vs. 24 years), and the rate 
of hearing loss was also significantly lower. Thus, it was 
shown that α5-positive cases may exhibit a mild clinical 
picture [17]. Similar results were also recently published 
by a different group [31]. These cases with α5-positive 
expression in GBM possessed non-truncating (missense or 
in-frame deletion) mutations or somatic mosaic mutations 
in COL4A5 [17].
Treatment
There is currently no radical therapy for AS; treatment is 
only performed for the purpose of delaying progression to 
renal failure using nephroprotective drugs. A randomized 
controlled trial (RCT) is underway in Germany (EARLY 
PRO-TECT ALPORT study) for confirming nephroprotec-
tive effects. Two RCT trial results have been previously 
published examining reduction of urine protein levels by 
angiotensin-converting enzyme inhibitors (ACEIs) and angi-
otensin receptor blockers (ARBs) in AS [32, 33]. One com-
pared losartan (ARB) and placebo, while another compared 
enalapril (ACEI) and losartan; both RCTs showed urine 
protein-reducing effects in both ACEI and ARB. A large 
retrospective study reported that ACEIs have the effect of 
delaying the progression to ESRD in AS [34]. Recently pub-
lished expert guidelines recommend that male patients initi-
ate treatment with ACEI from the time of diagnosis with AS 
[35]. Meanwhile, in female cases, it is recommended to start 
treatment at the time when urinary protein is detected, in 
addition to urine occult blood [35]. For ARAS, ACEI should 
be started at the time of diagnosis regardless of gender and, 
for ADAS, it should be initiated at the time when urinary 
protein is detected. No clinical trial has been performed 
comparing single (ACEI or ARB) and double block (ACEI 
and ARB); theoretically, double block can show a stronger 
renoprotective effect, and is already applied in clinical set-
tings. It was previously reported that cyclosporine treatment 
for AS significantly reduced urine protein levels and showed 
renoprotective effects in long-term follow-up [36, 37]. How-
ever, three recent reports showed that, although cyclosporine 
had strong effects for reducing urine protein, it accelerated 
interstitial fibrosis and had no renoprotective effects [38–40].
Regarding kidney transplantation, good results have been 
obtained compared with those in other kidney diseases; how-
ever, in 2–5% of cases, anti-GBM antibody is produced, 
leading to rapid graft loss [41]. There is no curative therapy 
for hearing impairment; only symptomatic treatment is avail-
able, such as the use of a hearing aid.
Some new drugs have entered clinical trials, such as 
bardoxolone methyl (Phase II/III) and RG-012 (effect on 
microRNA-21 interference, Phase II). Other therapies that 
have thus far been reported to show effects by in vivo and 
in vitro trials are as follows: (1) treatment with stem cells 
[42] and (2) treatment to control intracellular signal trans-
duction (USAG-1) [43]. Further expected treatments are as 
follows: (1) nonsense read-through therapy [44] and (2) exon 
skipping therapy with antisense oligonucleotides or chemi-
cal compounds [45, 46]. Notably, our group is working to 
develop exon skipping therapy using antisense oligonucleo-
tide (ASO). ASO will bind to the exonic splicing enhancer 
region and disturb the targeted exon at the point of splic-
ing; this will lead to exon skipping. As described above, 
when the skipped exon nucleotide number is a multiple of 
3, it change the severe phenotype with nonsense mutation 
to a milder phenotype with an in-frame deletion. We have 
already obtained good results in vitro and are proceeding to 
an in vivo trial with an animal model.
The border between TBM and AS
An issue of particular interest among experts in the field 
of AS is the differential diagnosis between AS and TBM. 
AS has generally been defined as progressive nephritis, 
sensorineural hearing loss, and specific eye abnormalities; 
TBM is generally defined as hematuria with/without mild 
proteinuria, with diffuse thinning of GBM that does not 
result in renal failure. There remains no clear delineation 
between the two diseases and leading clinical nephrologists 
are quite confused. Most heterozygous carriers of variants 
in COL4A3 or COL4A4 or some females with heterozygous 
mutations in COL4A5 show only hematuria without pro-
teinuria; those cases are not diagnosed with AS, according to 
its current definition. It is well-known that most cases with 
benign familial hematuria possess heterozygous mutations 
in either COL4A3 or COL4A4, and most will not develop 
ESRD [47]. It is also well-known that, in cases with only 
hematuria without proteinuria, ESRD will never develop 
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[9]. In EM findings, these cases typically show only TBM 
without lamellation of the lamina densa [7, 14]. In contrast, 
cases with ADAS begin to show proteinuria at the median 
age of 17 years; for females with XLAS, the equivalent age 
is 7 years. These findings indicate that there is no clear dis-
tinction between these two diseases, which presents difficul-
ties for physicians when attempting to make a differential 
diagnosis. We have experienced some cases exhibiting only 
hematuria at a young age, which were diagnosed with TBM; 
these patients then missed annual check-ups and developed 
ESRD at approximately 60 years of age (personal experi-
ence). ACEI can delay the age of developing ESRD, even 
in male cases of XLAS with the most severe phenotype. 
This indicates that ACEI can remarkably delay the age of 
ESRD development for cases with much milder phenotypes 
of ADAS. As experts in this field, we are responsible for 
ensuring that, in AS cases, the opportunity to begin treat-
ment by ACEI is not missed. Diagnosis of TBM tends to 
underestimate the risk of progressive kidney disease. There-
fore, some experts have recently asserted that patients with 
hematuria, TBM, and heterozygous mutations in COL4A3 
or COL4A4 should be classified as cases of autosomal AS. 
In addition, all females with XLAS should also be classified 
as cases of XLAS. These changes of definition of AS may 
eliminate TBM nephropathy as a diagnostic entity [48].
Conclusion
Recent advances in genetic analysis have provided us with a 
deeper understanding of the pathophysiological mechanisms 
of inherited kidney diseases. Based on precise genetic infor-
mation, we came to understand the mechanisms of onset of 
milder phenotypes in AS. As experts in this field, we must 
devote our energies to creating a system that allows patients 
with AS to be diagnosed at an early stage and to start appro-
priate treatment. For this reason, we need to change the defi-
nition of AS to include all cases with nephropathy caused by 
COL4A3, COL4A4, or COL4A5 gene variants and eliminate 
the disease entity of TBM; this will allow patients to avoid 
missing the opportunity to start appropriate treatment as 
early as possible.
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